EDN1 and colorectal carcinoma: Mechanistically, melatonin treatment inhibits both FoxO1 and NF-κβ activity, which positively regulates endothelin-1 promoter activity, thereby blocking CRC progression via melatonin-reduced endothelin-1 expression [139].